Introduction

In 1880, British ophthalmologist Henry Eales described Eales' disease for the first time⁽¹⁾. Recurrent vitreous hemorrhaging is a hallmark of Eales' disease⁽²⁾. The systemic anti- tuberculosis and the steroids usually control the disease and subsequently resolve the vitreous hemorrhage⁽³⁾, but when the vitreous hemorrhage persists, anti-VEGF is an option⁽⁴⁾.

1. Eales Primary retinal hemorrhage in young men. Ophthalmic Review. 1882;1:41-6.
2. Das T, Pathengay A, Hussain N, Biswas Eales’ disease: diagnosis and management. Eye. 2010;24(3):472-82.
3. Abdullah Unilateral Eales disease with presumed tubercular etiology, three case reports. Health Science Journal. 2020;14(4):1-5.
4. Patwardhan SD, Azad R, Shah BM, Sharma Role of intravitreal bevacizumab in Eales disease with dense vitreous hemorrhage: a prospective randomized control study. Retina. 2011;31(5):866-70.
5. Abdullah A Novel Approach to Prevent Intraocular Pressure Spikes and Reflux During Intravitreal Injections.

Anya Lev

Norilsk Health Care, Norilsk-Russia